BONESUPPORT announces - De Novo application for CERAMENT G has been submitted to the FDA
Lund, Sweden, 17.30 CET, 17 April 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries today announced that the company has submitted a De Novo application to the US Food and Drug Administration (FDA) to obtain a market approval for the company's antibiotic-releasing product CERAMENT® G. The application is specified for the indication osteomyelitis (bone infection) and can potentially result in an approval at the latter end of 2020. For more information contact: BONESUPPORT ABEmil Billbäck, CEO+46 (0) 46 286 53 70 Håkan Johansson,